RECRUITING

Dietary Omega-7 Palmitoleic Acid-Rich Oil on Lipoprotein Metabolism and Satiety in Adults

Conditions

Cardiovascular Disease Omega-7 Palmitoleic Acid Monounsaturated Fatty Acids Lipoproteins Satiety

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Background: Omega-7 fatty acids are found in the oil extracted from certain fish and nuts like macadamia. Palmitoleic acid is one of the most common omega-7 fatty acids. Many studies suggest that this oil is good for heart health. Researchers want to find out more about these potential benefits. Objective: To study how oil enriched with palmitoleic acid (Omega-7 oil) affects metabolism. Eligibility: Healthy adults at least 18 years old with no known history of cardiovascular disease. Subjects not allergic to fish oil and fish products Females that are not pregnant and are not planning a pregnancy during the length of the study Design: Participants will be screened with questions about their health, medical history, and medicines they take. Participants will have 4 visits over 24 weeks. The visits may include: * Blood drawn from a vein in the arm by a needle stick. Sometimes participants will have to fast before the blood draw. * Vital signs (blood pressure, heart rate, and temperature) taken * Body mass index measured * Cardio-Ankle Vascular Index test may be performed. The stiffness of the participant s arteries will be measured by reading blood pressure in the arms and legs and monitoring the heart. * Optional stool samples * Pregnancy test * A short review of participants physical activity and diet * A supply of dietary supplements to take between visits. Participants will take 4 gel capsules a day. Participants will keep a food and exercise journal Compensation will be provided to subjects that complete the study Check your eligibility for this study by clicking here: https://www.surveymonkey.com/r/DietaryOmega

Official Title

Effect of Dietary Omega-7 Palmitoleic Acid-Rich Oil on Lipoprotein Metabolism and Satiety in Adults

Quick Facts

Study Start:2018-07-31

Study Completion:2026-07-31

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT03372733

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 99 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Male and female participants 18 years of age or above. * Subject must be healthy, with no known history of cardiovascular disease. * Post-menopausal or women of childbearing potential must be non-lactating and using an effective form of birth control during the course of the study. * Subject understands protocol and provides written, informed consent in addition to a willingness to comply with specified follow-up evaluations. * Subjects with triglyceride levels above 100 mg/dL	* Pregnancy, planned pregnancy (within the study period), or women currently breastfeeding. * Subjects with allergy or known hypersensitivity to fish, omega-3-acid ethyl esters, omega-7 ethyl esters, other related drugs, or any component of study drugs * Subjects with weight changes greater than 20% over the past 3 months. * Subjects planning a significant change in diet or exercise levels. * Subjects already consuming more than 2 g per day of MUFA, PUFA or other forms of fatty acid supplement if determined by the investigator as having a potential to interfere in the data quality or patient safety. * Subjects with chronic diarrhea, gastric bypass or lap-band procedures, ostomies, bowel motility problems, or other known conditions that could affect intestinal fat absorption. * Subjects with any acute and life-threatening condition, such but not limited to as prior sudden cardiac arrest, acute myocardial infarction (last three months), stroke, embolism as per investigator assessment. * Subjects taking supplements or medications that affect lipoproteins for at least the past 8 weeks, such as fish oil supplements, bile-acid sequestrants, plant sterol supplements, fibrates, statins, Niacin or PCSK9 inhibitors. * Subjects being treated with tamoxifen, estrogens, or progestins that have not been stable for \>4 weeks. * Subjects initiating new medications or patients on multiple medications may also be excluded according to investigator discretion. * Anticipated surgery during the study period. * Liver enzymes (AST or ALT) levels above 3x upper limit of normal. * Blood donation in the last 2 weeks or planned blood donation during the study. * Subjects requiring regular transfusions for any reason. * Subjects may also be excluded for any reason that may compromise their safety or the accuracy of research data or for not complying with protocol directions. * Abnormal baseline laboratory values that are considered not clinically significant by the PI will not exclude the subject.

Inclusion Criteria

Exclusion Criteria

* Male and female participants 18 years of age or above.
* Subject must be healthy, with no known history of cardiovascular disease.
* Post-menopausal or women of childbearing potential must be non-lactating and using an effective form of birth control during the course of the study.
* Subject understands protocol and provides written, informed consent in addition to a willingness to comply with specified follow-up evaluations.
* Subjects with triglyceride levels above 100 mg/dL

* Pregnancy, planned pregnancy (within the study period), or women currently breastfeeding.
* Subjects with allergy or known hypersensitivity to fish, omega-3-acid ethyl esters, omega-7 ethyl esters, other related drugs, or any component of study drugs
* Subjects with weight changes greater than 20% over the past 3 months.
* Subjects planning a significant change in diet or exercise levels.
* Subjects already consuming more than 2 g per day of MUFA, PUFA or other forms of fatty acid supplement if determined by the investigator as having a potential to interfere in the data quality or patient safety.
* Subjects with chronic diarrhea, gastric bypass or lap-band procedures, ostomies, bowel motility problems, or other known conditions that could affect intestinal fat absorption.
* Subjects with any acute and life-threatening condition, such but not limited to as prior sudden cardiac arrest, acute myocardial infarction (last three months), stroke, embolism as per investigator assessment.
* Subjects taking supplements or medications that affect lipoproteins for at least the past 8 weeks, such as fish oil supplements, bile-acid sequestrants, plant sterol supplements, fibrates, statins, Niacin or PCSK9 inhibitors.
* Subjects being treated with tamoxifen, estrogens, or progestins that have not been stable for \>4 weeks.
* Subjects initiating new medications or patients on multiple medications may also be excluded according to investigator discretion.
* Anticipated surgery during the study period.
* Liver enzymes (AST or ALT) levels above 3x upper limit of normal.
* Blood donation in the last 2 weeks or planned blood donation during the study.
* Subjects requiring regular transfusions for any reason.
* Subjects may also be excluded for any reason that may compromise their safety or the accuracy of research data or for not complying with protocol directions.
* Abnormal baseline laboratory values that are considered not clinically significant by the PI will not exclude the subject.

Contacts and Locations

Study Contact

Joy Lynne V Freeman

CONTACT

(301) 480-7632

joylynne.freeman@nih.gov

Principal Investigator

Marcelo J Amar, M.D.

PRINCIPAL_INVESTIGATOR

National Heart, Lung, and Blood Institute (NHLBI)

Study Locations (Sites)

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892

United States

Collaborators and Investigators

Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Marcelo J Amar, M.D., PRINCIPAL_INVESTIGATOR, National Heart, Lung, and Blood Institute (NHLBI)

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2018-07-31

Study Completion Date2026-07-31

Study Record Updates

Study Start Date2018-07-31

Study Completion Date2026-07-31

Terms related to this study

Keywords Provided by Researchers

Omega-7
Palmitoleic Acid
Monounsaturated Fatty Acids
Lipoproteins
Satiety

Additional Relevant MeSH Terms

Cardiovascular Disease